Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Department of Urology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Curr Treat Options Oncol. 2021 Apr 17;22(6):47. doi: 10.1007/s11864-021-00846-z.
Prostate cancer is the second leading cause of cancer death in men, and cardiovascular disease is the number one cause of death in patients with prostate cancer. Androgen deprivation therapy, the cornerstone of prostate cancer treatment, has been associated with adverse cardiovascular events. Emerging data supports decreased cardiovascular risk of gonadotropin releasing hormone (GnRH) antagonists compared to agonists. Ongoing clinical trials are assessing the relative safety of different modalities of androgen deprivation therapy. Racial disparities in cardiovascular outcomes in prostate cancer patients are starting to be explored. An intriguing inquiry connects androgen deprivation therapy with reduced risk of COVID-19 infection susceptibility and severity. Recognition of the cardiotoxicity of androgen deprivation therapy and aggressive risk factor modification are crucial for optimal patient care.
前列腺癌是男性癌症死亡的第二大主要原因，心血管疾病是前列腺癌患者的头号死因。去势治疗是前列腺癌治疗的基石，与不良心血管事件相关。新出现的数据支持与激动剂相比，促性腺激素释放激素 (GnRH) 拮抗剂降低心血管风险。正在进行的临床试验正在评估不同去势治疗方式的相对安全性。前列腺癌患者心血管结局的种族差异开始得到探索。一个有趣的研究将去势治疗与降低 COVID-19 感染易感性和严重程度联系起来。认识到去势治疗的心脏毒性和积极的危险因素改变对于最佳患者护理至关重要。
